Management of patients with refractory immune thrombocytopenic purpura.
about
Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation.Treatment of chronic immune thrombocytopenic purpura: the patients' perspective.Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia.New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.New insights and therapeutics for immune-mediated thrombocytopenia.Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective.Response to mercaptopurine for refractory autoimmune cytopenias in children.Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Single nucleotide polymorphism in the methyl-CpG binding domain 4 gene and the risk for immune thrombocytopenic purpura in Chinese population.Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomyVery long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.Pathophysiology and therapeutic options in primary immune thrombocytopenia.Current treatment options for primary immune thrombocytopenia.Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cellsThe scintigraphic index spleen/liver at 30 minutes predicts the success of splenectomy in persistent and chronic primary immune thrombocytopenia.Patient-reported treatment burden of chronic immune thrombocytopenia therapies.Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist.High-dose methylprednisolone pulse therapy upregulated FcγRIIb expression on B cells in primary Sjögren's syndrome patients with thrombocytopenia.Thrombocytopenia and thrombosis: a double-edged sword.The pharmacology and clinical application of thrombopoietin receptor agonists.Evaluation of 143 cases of immune thrombocytopenic purpura with regards to clinical course and response to treatment.An unusual occurrence of Kleine-Levin syndrome in a man with refractory immune thrombocytopenic purpura: a case report.Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports.Health-related quality of life in children with chronic immune thrombocytopenia in China.A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients.Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia.Immune Thrombocytopenia and Obesity: Predictive Relationship.Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study.Perioperative care of a patient with refractory idiopathic thrombocytopenic purpura undergoing total knee arthroplasty.Definition, diagnosis and treatment of immune thrombocytopenic purpura.Thrombopoietin receptor agonists (TPO-RAs) in patients with persistent or chronic immune thrombocytopenia (ITP).Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
P2860
Q30250259-32C38194-0D6F-4813-A81F-C5DD94AFB8CEQ33373525-89996A92-6F5C-4054-B47F-C1D2BE377530Q33374327-3A2E5935-A9E9-4D72-8D1E-EDDEE14A8C7AQ33374397-A2BC0850-09EF-4DA0-AE22-27F996C2A87DQ33376412-FA11389B-9A8E-41FD-8BB9-F5A159795860Q33377221-688A0B55-CB33-4ECC-8B01-30B2C1974EE4Q33377901-65E1C57F-100B-4824-AFAA-04CFE9EE0C85Q33378585-469958EB-F9C3-4899-83A8-7F23C4D48F31Q33380897-6152E22D-7179-4960-95BE-BE5658407FEEQ33387310-0A2E44C6-2FA5-4906-8B69-42E1D361927FQ33387735-AB519D0F-0E38-4082-9705-DFBE284ABEF0Q33387960-83325089-0299-44E7-AF01-3D5092FF3B21Q33392852-523A58D5-8B92-423E-A98E-D636CD30C788Q33393057-7A51BBE1-F8BE-4EA2-BDA8-319B13B7E00DQ33393344-7528DC45-6761-42B4-B4AB-5819A4F52C4BQ33393732-2D56506E-5CD7-4021-992E-C35E3E5C6613Q33394149-FD74F916-BCC3-4B72-848C-8C296D8F538CQ33395970-5321353F-4816-40B7-9B98-C6EDFBA8D392Q33397351-C6F77490-B2C8-4811-AF92-6C350AB94DBBQ33400348-2FEF538F-D631-4D35-AB4C-B553722CB8E2Q33401211-9B96AFBA-56B7-43B1-9C5D-1D79619B0740Q33406379-AD3E7A11-A495-4542-A46C-C06E39FF6903Q33409534-F5F24644-D117-48D1-8BA3-5B2CE87A3250Q33411317-52A7E57C-7D07-473F-8058-0A485E7B3DFFQ33417700-C0AA0CEC-4759-41BC-A916-FBF96E7723FBQ33419925-E8C6087E-EDAA-4760-8398-47ADD1C10664Q33422108-3EEEE120-7031-46D9-B295-13071A54497EQ33424451-261E0E6F-63B6-4B86-83CF-C7DB87AFEB64Q33424554-7E79AF42-3839-4B47-A71E-A926F1D427D1Q33430741-A75F857A-97FA-46DB-8FEA-1FBBA358D158Q33431123-11E07A6A-A092-49A7-A5D4-29D43687FC7BQ33431689-1EAE8A35-9BBF-41D3-B38F-F5ECC2ED4228Q33437508-3225EBD0-695F-4307-AA56-53C1AC299F41Q33437797-04C941F7-F92F-41D0-92F9-A83BBB4CFA2CQ33440332-757E1128-6F58-4E45-BB71-A1C1B00488ECQ38658259-62BA9865-8EA3-45C8-BF0E-38D514FD0F23Q41763490-BB95D427-1058-4502-B6C6-3DDC5B4425F5Q43120472-63D416CA-7F11-4DDC-A452-6277E3C7B208Q47305608-80FB28DC-B018-432E-8A20-80F92E6C52EDQ55332132-CD18BCF9-FFB0-440D-807C-1C6029325CAF
P2860
Management of patients with refractory immune thrombocytopenic purpura.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Management of patients with refractory immune thrombocytopenic purpura.
@ast
Management of patients with refractory immune thrombocytopenic purpura.
@en
type
label
Management of patients with refractory immune thrombocytopenic purpura.
@ast
Management of patients with refractory immune thrombocytopenic purpura.
@en
prefLabel
Management of patients with refractory immune thrombocytopenic purpura.
@ast
Management of patients with refractory immune thrombocytopenic purpura.
@en
P2860
P1476
Management of patients with refractory immune thrombocytopenic purpura.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2006.02013.X
P577
2006-08-01T00:00:00Z